Public Release: 

New study shows Emezine® demonstrates more efficient absorption

Versus swallowed form of prochlorperazine

SciWords

(Tampa, FL Dec. 12, 2005) --Accentia Biopharmaceuticals, Inc. (Accentia) (NASDAQ:ABPI) announced today the publication of a pharmacokinetic (PK) study regarding Emezine® (prochlorperazine maleate) a buccal tablet being developed for the intended treatment of severe nausea and vomiting (emesis). The findings, published in the December 2005 issue of the Journal of Clinical Pharmacology, demonstrated that the mucosa absorption of Emezine buccal tablet delivered more than twice the plasma concentrations of the active ingredient, prochlorperazine, with significantly less intra-patient variability than that obtained from a standard oral swallow tablet.

If approved by the FDA, Emezine, a dissolving tablet placed between the lip and gum (also known as the buccal area), may avoid the need for a patient to swallow a product during a period of nausea, which Accentia believes, offers a more patient-friendly alternative to injections and rectal suppositories.

As previously announced Accentia signed a licensing agreement with Emezine's developer, BioDelivery Sciences International, Inc. for the exclusive sales and marketing rights for the US market and its territories. Emezine, upon approval, will be marketed through Accentia's specialty pharmaceutical division, TEAMM Pharmaceuticals.

Nausea and vomiting are commonly reported symptoms in the US and can be the result of a wide number of diseases or as a side effect of some treatments. Some of the most common treatment-induced causes of emesis are a result of chemotherapy, pain medications, antibiotics and anesthesia used in surgical procedures. Nausea and vomiting also often accompany migraines, flu, stomach ailments such as gastroenteritis or motion sickness. In addition to the impact on quality of life, severe emesis can lead to serious consequences of electrolyte imbalances and dehydration.

Gary Cantrell, Executive Vice President of Sales and Marketing for Accentia's specialty pharmaceuticals division said, "Prochlorperazine is widely used for the relief of nausea and vomiting however physicians outside the hospital and clinic have been limited to prescribing a suppository or standard oral swallow tablet. In our market research, physicians responded very favorably to Emezine and indicated that it would be an important part of their treatment options for patients experiencing emesis."

###

About Accentia Biopharmaceuticals
Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of late-stage clinical products in the therapeutic areas of respiratory disease and oncology. The company's SinuNaseTM product is a novel application and formulation of a known anti-fungal being developed under an Investigational New Drug Application (IND) to treat chronic sinusitis (rhinosinusitis). SinuNase was originally developed by and licensed from the Mayo Foundation for Medical Education and Research. BiovaxIDTM is a patient-specific anti-cancer vaccine intended for the treatment of follicular non-Hodgkin's lymphoma. BiovaxID is being developed by Accentia's subsidiary Biovest International, Inc. and it is currently in a pivotal Phase 3 clinical trial started by the National Cancer Institute. In addition, Accentia has a growing specialty pharmaceutical business with a portfolio of currently marketed products plus a pipeline of additional products under development by third parties. For further information, please visit Accentia's website: http://www.accentia.net.

About BioDelivery Sciences International
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty biopharmaceutical company that is exploiting its licensed and patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, clinically-significant new formulations of proven therapeutics targeted at "acute" treatment opportunities such as pain, anxiety, nausea and vomiting and infections. The company's drug delivery technologies include: (i) the patented Bioral® nanocochleate technology, designed for a potentially broad base of applications, and (ii) the patented BEMATM (transmucosal or mouth) drug delivery technology. The company's headquarters are located in Morrisville, North Carolina and its principal laboratory is located in Newark, New Jersey.

Forward-Looking Statements
Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about Emezine and any other statements relating to Accentia's products, product candidates, and product development programs. Such statement may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Accentia's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of Accentia's clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in Accentia's filings with the Securities and Exchange Commission. All forward looking statements are qualified in their entirety by this cautionary statement, and Accentia undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

Contact: Accentia Biopharmaceuticals, Tampa
Sherran Brewer, 866-481-9020
sbrewer@accentia.net

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.